Haitong International initiates coverage on Giant Biogene with an Outperform rating in its Hong Kong stock ratings summary.

Cailian Press will regularly compile ratings and target prices from various institutions for Hong Kong stocks.

cls.cn15:10

CICC: The acquisition by Sinopharm (01177.HK) can enhance its strategic positioning in the weight management and metabolism sector. Maintain target price at HKD 8.9.

According to a research report by CICC, Sino Biopharm (01177.HK) announced the 100% acquisition of Hejiya Bio for RMB 1.2 billion. Hejiya Bio is deeply engaged in the siRNA sector, with a key focus on three major chronic disease areas: weight management and metabolism, cardiovascular and cerebrovascular diseases, and the nervous system. Its core platform possesses differentiated competitive advantages. The report notes that existing therapies in the chronic disease field generally face limitations in efficacy, safety risks, and low patient compliance, indicating significant unmet clinical needs. This acquisition is expected to help Sino Biopharm build an innovative pipeline for next-generation cardiovascular treatments and strengthen its presence in the weight management and metabolic fields.

AASTOCKS11:11

At the 'American Pharma Gala,' Chinese pharmaceutical companies have transitioned from 'optional consumption' to 'essential consumption.'

According to a JPMorgan report, China's innovative drug sector has evolved from being an 'optional choice' to becoming a category that multinational pharmaceutical companies must systematically evaluate during the asset screening phase. In certain areas such as oncology, autoimmune diseases, and metabolic conditions, some Chinese pharmaceutical companies have advanced to the forefront of global competition for the same therapeutic targets. This leadership is not primarily reflected in innovation of mechanisms but rather in clinical execution efficiency, patient enrollment speed, and the pace of advancing indications.

wallstreetcnJan 14 14:55

Sino Biopharm To Remain Active in M&A, Says Chair

Yahoo FinanceJan 14 13:11

Goldman Sachs has assigned a "Buy" rating to Sino Biopharm (01177.HK) with a target price of HKD 6.19.

Goldman Sachs issued a research report granting Sino Biopharm (01177.HK) a "Buy" rating with a target price of HKD 6.19. This target price is based on a 12-month sum-of-the-parts valuation, utilizing a discounted cash flow method for the innovative drug pipeline, which is valued at RMB 69.3 billion. The generics business is valued at RMB 46.8 billion based on a 12x price-to-earnings ratio and a five-year compound annual growth rate of 5%. Sino Biopharm announced the acquisition of 100% equity in Hejia for a total consideration of RMB 1.2 billion (hereinafter the same), of which approximately RMB 1.1 billion will be paid in cash, with the remaining RMB 97 million to be paid in installments through the issuance of new shares. Hejia is a clinical-stage...

AASTOCKSJan 14 12:06

Citi: China Biologic Products (01177.HK) acquisition of an siRNA pharmaceutical company enhances its out-licensing potential. Target price set at HKD 10.8, recommendation is 'Buy'.

According to a Citi research report, Sino Biopharm (01177.HK) announced the acquisition of Hygieia, a private biotech company specializing in small interfering RNA (siRNA) drugs, for a maximum consideration of RMB 1.2 billion. Hygieia has developed multiple differentiated delivery platforms, with its R&D pipeline including drug candidates such as Kylo-11, Kylo-12, Kylo-0603, HJY-10, and HJY-02. Through this acquisition, Sino Biopharm will build a next-generation cardiovascular innovation pipeline, strengthen its presence in weight management and metabolic disease sectors, and expand into new areas.

AASTOCKSJan 14 11:15